| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5690661 | Gynecologic Oncology | 2017 | 6 Pages |
Abstract
Despite gains in QALY and PFS, the addition of B to single agent CT for treatment of platinum-resistant recurrent ovarian cancer is not cost effective. Benefits, risks, and costs associated with treatment should be taken into consideration when prescribing chemotherapy for this patient population.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Weiya Z. Wysham, Elisabeth M. Schaffer, Theresa Coles, Dario R. Roque, Stephanie B. Wheeler, Kenneth H. Kim,